Molecular Templates, Inc. (MTEM)

NASDAQ: MTEM · IEX Real-Time Price · USD
1.340
-0.050 (-3.60%)
Jul 19, 2024, 3:59 PM EDT - Market closed
-3.60%
Market Cap 8.82M
Revenue (ttm) 31.76M
Net Income (ttm) -18.40M
Shares Out 6.58M
EPS (ttm) -1.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,790
Open 1.420
Previous Close 1.390
Day's Range 1.340 - 1.420
52-Week Range 1.010 - 9.450
Beta 1.19
Analysts n/a
Price Target n/a
Earnings Date Aug 8, 2024

About MTEM

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refract... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Eric E. Poma Ph.D.
Employees 62
Stock Exchange NASDAQ
Ticker Symbol MTEM
Full Company Profile

Financial Performance

In 2023, MTEM's revenue was $57.31 million, an increase of 190.10% compared to the previous year's $19.75 million. Losses were -$8.12 million, -91.24% less than in 2022.

Financial Statements

News

Molecular Templates, Inc. Provides Interim Update

AUSTIN, Texas, June 03, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage company focused on the discovery and development of target...

6 weeks ago - GlobeNewsWire

Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update

AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and deve...

2 months ago - GlobeNewsWire

Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patie

AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and de...

3 months ago - GlobeNewsWire

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and de...

4 months ago - GlobeNewsWire

Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement

AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and de...

4 months ago - GlobeNewsWire

Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March - Inspire Veterinary (NASDAQ:IVP), Fractyl Health (NASDAQ:GUTS)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: GUTSIVPOMPACB
4 months ago - Benzinga

Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

AUSTIN, Texas, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics wi...

5 months ago - GlobeNewsWire

Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update

AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and dev...

8 months ago - GlobeNewsWire

Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors

AUSTIN, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics fo...

9 months ago - GlobeNewsWire

Molecular Templates to Participate in Upcoming Investor Conferences

AUSTIN, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and dev...

9 months ago - GlobeNewsWire

Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer

AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics f...

10 months ago - GlobeNewsWire

Molecular Templates Announces 1-for-15 Reverse Stock Split

AUSTIN, Texas, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) (the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with p...

1 year ago - GlobeNewsWire

Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update

AUSTIN, Texas, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and dev...

1 year ago - GlobeNewsWire

Molecular Templates Announces Executive Leadership Changes

AUSTIN, Texas, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics fo...

1 year ago - GlobeNewsWire

Molecular Templates Announces Up to $40 Million Private Placement Offering

AUSTIN, Texas, July 13, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and dev...

1 year ago - GlobeNewsWire

Molecular Templates Announces Debt Payoff and Restructuring

AUSTIN, Texas, June 16, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and dev...

1 year ago - GlobeNewsWire

Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma

AUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and dev...

1 year ago - GlobeNewsWire

Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

AUSTIN, Texas, May 26, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and deve...

1 year ago - GlobeNewsWire

Molecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update

Advancing clinical development of MT-6402, MT-8421, and MT-0169, and preclinical activities related to Bristol Myers Squibb collaboration

1 year ago - GlobeNewsWire

Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169

Partial hold based on previously disclosed cardiac events at 50 mcg/kg cohort; FDA to review safety data in lower dose cohorts Partial hold based on previously disclosed cardiac events at 50 mcg/kg co...

1 year ago - GlobeNewsWire

Molecular Templates, Inc. Reports Fourth Quarter 2022 Financial Results and Business Update

Announces strategic reprioritization to focus on clinical development of MT-6402, MT-8421, and MT-0169, and preclinical activities related to BMS collaboration, and related workforce reduction Announc...

1 year ago - GlobeNewsWire

Molecular Templates Announces IND Acceptance by FDA for MT-8421 ETB Program Targeting CTLA-4

AUSTIN, Texas, March 09, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and de...

1 year ago - GlobeNewsWire

Molecular Templates Announces Participation in Upcoming Conferences

AUSTIN, Texas, March 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and de...

1 year ago - GlobeNewsWire

Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting

AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and dev...

1 year ago - GlobeNewsWire

Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI's 5th Annual HealthCONx Conference and Piper Sandler's 34th Annual Healthcare Conference

AUSTIN, Texas, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and dev...

1 year ago - GlobeNewsWire